Woodline Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Woodline Partners’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-450,199	Closed	-$3.39M	–	915
2024 Q4	$3.39M	Buy	+450,199	New	+$3.42M	0.02%	564
2023 Q2	–	Sell	-701,580	Closed	-$5.85M	–	643
2023 Q1	$5.85M	Sell	701,580 -1,369,403	-66%	-$13.2M	0.08%	270
2022 Q4	$23.8M	Buy	+2,070,983	New	+$25.8M	0.32%	83
2021 Q1	–	Sell	-155,844	Closed	-$1.16M	–	431
2020 Q4	$1.16M	Sell	155,844 -712,864	-82%	-$3.67M	0.03%	207
2020 Q3	$2.98M	Sell	868,708 -722,133	-45%	-$3.09M	0.1%	157
2020 Q2	$7.58M	Buy	1,590,841 +336,314	+27%	+$1.34M	0.3%	84
2020 Q1	$2.51M	Sell	1,254,527 -1,163,302	-48%	-$3.2M	0.18%	112
2019 Q4	$8.34M	Buy	+2,417,829	New	+$6.08M	0.34%	73

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners's BCRX Position: Q1 2025 in Review

Woodline Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2025, closing a stake of 450,199 shares — an estimated $3.39M sold.

Woodline Partners first reported a position in BCRX in Q4 2019 and held it in 8 quarters. The position peaked at $23.8M in Q4 2022. 274 funds tracked by Wall St. Rank hold BCRX as of Q1 2025.

Woodline Partners reported no remaining BioCryst Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Woodline Partners sold 450,199 BioCryst Pharmaceuticals shares in Q1 2025, an estimated $3.39M.
Woodline Partners first reported a position in BioCryst Pharmaceuticals in Q4 2019 and held it in 8 quarters.
Woodline Partners's BioCryst Pharmaceuticals position peaked at $23.8M in Q4 2022.
274 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2025.

Based on Woodline Partners's 13F filing for Q1 2025, filed 15 May 2025.